Exploring the Feasibility and Patient Acceptance of RAGT for Overground Ambulation in Adults With Guillain-Barré Syndrome: A Scoping Review.
Joon Sin Ser, Siew Kwaon Lui
PMID 42326576WHAT IT FOUND
Across four small studies and 19 adults with Guillain-Barré syndrome, patients completed robot-assisted gait training and only one adverse event was reported, pain from a device's saddle.
No study compared it with conventional therapy, so whether it improves walking is unknown.
Key findings
01Four studies met the inclusion criteria and together reported on 19 adults with Guillain-Barré syndrome or AIDP: two case reports, one mixed-methods feasibility study and one cross-sectional study.
02Only one adverse event was reported across all four studies: pain from the saddle interface in the cross-sectional study of 15 patients.
03None of the included studies compared robot-assisted gait training with conventional gait rehabilitation, so the improvements reported cannot be attributed to the robot rather than to concurrent therapies or natural recovery.
STILL TO COME
How it was doneWhat they foundWhat it means for PTs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
Only four studies met the inclusion criteria and together they reported on 19 adults; two were single case reports, so this is a description of what has been tried, not evidence that it works. No included study compared robot-assisted gait training with conventional rehabilitation, so the functional gains reported could come from the therapy patients were already receiving or from the natural recovery course of GBS. The studies used different robots, different doses and different points in the disease course, so they cannot be compared with one another and no device or protocol can be recommended over another. Only 2 of the 26 patients in the feasibility study had an inflammatory polyneuropathy, so most of that study's data comes from other neurologic conditions. Patient acceptance was not measured in the GBS patients themselves; the review reasons about it from stroke, spinal cord injury and multiple sclerosis populations, which the authors say cannot be directly extrapolated to GBS. The costs quoted are high: the review notes a Lokomat price of EUR 881,292 in 2022 and an overground robotic exoskeleton price of USD 150,000, excluding maintenance and repair.
Declared interests
The authors state they have no financial or nonfinancial disclosures to make in relation to this project. No funding source is reported in the text. Three manufacturers are named as suppliers of the devices used in the reviewed studies (Hocoma, Tyromotion and CUREXO), but the paper does not say whether they funded or contributed to this work.
The easy way to misread this
Do not read the improvements reported in these studies as evidence that robot-assisted gait training improves walking in Guillain-Barré syndrome. None of the four studies compared it with conventional rehabilitation, and two were single case reports, so any gains could come from the therapy the patients were already receiving or from natural recovery. One of the reported patients was already walking with supervision or independently before the robot was introduced.
Summarised by AI from the full paper, without a clinician reviewing it. Check it against the source before it changes what you do. Read it on PubMed →